These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11409037)
41. Immunoaffinity chromatographic and immunoprecipitation methods combined with mass spectrometry for characterization of circulating transthyretin. Heegaard NH; Hansen MZ; Sen JW; Christiansen M; Westermark P J Sep Sci; 2006 Feb; 29(3):371-7. PubMed ID: 16544878 [TBL] [Abstract][Full Text] [Related]
42. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081 [TBL] [Abstract][Full Text] [Related]
43. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Colon W; Kelly JW Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650 [TBL] [Abstract][Full Text] [Related]
44. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022 [TBL] [Abstract][Full Text] [Related]
45. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. Koike H; Ando Y; Ueda M; Kawagashira Y; Iijima M; Fujitake J; Hayashi M; Yamamoto M; Mukai E; Nakamura T; Katsuno M; Hattori N; Sobue G J Neurol Sci; 2009 Dec; 287(1-2):178-84. PubMed ID: 19709674 [TBL] [Abstract][Full Text] [Related]
46. A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry. Pont L; Sanz-Nebot V; Vilaseca M; Jaumot J; Tauler R; Benavente F Talanta; 2018 May; 181():87-94. PubMed ID: 29426546 [TBL] [Abstract][Full Text] [Related]
47. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro. Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615 [TBL] [Abstract][Full Text] [Related]
49. Biophysical characterization and modulation of Transthyretin Ala97Ser. Liu YT; Yen YJ; Ricardo F; Chang Y; Wu PH; Huang SJ; Lin KP; Yu TY Ann Clin Transl Neurol; 2019 Oct; 6(10):1961-1970. PubMed ID: 31502419 [TBL] [Abstract][Full Text] [Related]
50. Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy. Misumi Y; Ando Y; Ueda M; Obayashi K; Jono H; Su Y; Yamashita T; Uchino M J Pathol; 2009 Dec; 219(4):481-90. PubMed ID: 19790249 [TBL] [Abstract][Full Text] [Related]
51. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Blake C; Serpell L Structure; 1996 Aug; 4(8):989-98. PubMed ID: 8805583 [TBL] [Abstract][Full Text] [Related]
53. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry. Kingsbury JS; Théberge R; Karbassi JA; Lim A; Costello CE; Connors LH Anal Chem; 2007 Mar; 79(5):1990-8. PubMed ID: 17261023 [TBL] [Abstract][Full Text] [Related]
54. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961 [TBL] [Abstract][Full Text] [Related]
55. Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin. Cordeiro Y; Kraineva J; Suarez MC; Tempesta AG; Kelly JW; Silva JL; Winter R; Foguel D Biophys J; 2006 Aug; 91(3):957-67. PubMed ID: 16698785 [TBL] [Abstract][Full Text] [Related]
56. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763 [TBL] [Abstract][Full Text] [Related]
57. Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. Redondo C; Damas AM; Olofsson A; Lundgren E; Saraiva MJ J Mol Biol; 2000 Dec; 304(3):461-70. PubMed ID: 11090287 [TBL] [Abstract][Full Text] [Related]
58. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. Gorevic PD; Prelli FC; Wright J; Pras M; Frangione B J Clin Invest; 1989 Mar; 83(3):836-43. PubMed ID: 2646319 [TBL] [Abstract][Full Text] [Related]
59. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941 [TBL] [Abstract][Full Text] [Related]
60. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. Quintas A; Saraiva MJ; Brito RM FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]